Group 1 - Innocan Pharma Corporation anticipates listing on NYSE American around January 7, 2026, pending approval of its application and compliance with exchange rules [1] - The company is conducting a concurrent offering of its securities, subject to market conditions and regulatory approval [2] - Innocan's common shares will continue to trade on the OTC Markets' OTCQB until January 6, 2026, after which trading will terminate upon NYSE listing [3] Group 2 - Innocan is an innovator in pharmaceuticals and wellness, developing a CBD-loaded liposome drug delivery platform for non-opioid pain management [5] - The wellness segment includes a portfolio of self-care and beauty products, marketed through its 60% owned subsidiary, BI Sky Global Ltd. [5]
Innocan Pharma Corporation Anticipates Listing on the NYSE American Stock Exchange with Concurrent Offering
Prnewswire·2026-01-02 12:00